Massey and VCU Community Memorial Hospital open Southern Virginia’s first radiation treatment center
Community citizens, healthcare leaders, local politicians and officials gathered at VCU Community Memorial Hospital (VCU CMH) on August 14 for the official grand opening celebration of the Solari Radiation Therapy Center, the first and only radiation therapy center in the Southern Virginia Area. The center is a joint venture between VCU CMH and VCU Massey Cancer Center, who together provide VCU CMH’s Cancer and Specialty Care.
“Beat the heat” tips for cancer patients
With Virginia and other parts of the nation experiencing a summer heat wave, it is important for cancer patients to take the necessary precautions to protect themselves. Here are some tips to help keep yourself or your loved one cool this summer: limit sun exposure, use sunscreen, cover up...
New protein discovered with vast potential for treatment of cancer and other diseases
In cancer research, discovering a new protein that plays a role in cancer is like finding a key and a treasure map: follow the clues and eventually there could be a big reward. At least that’s the hope from a new study published in the journal Nature that discovered a novel protein called ceramide-1 phosphate transport protein (CPTP) – a finding that could eventually lead to the development of new drugs to treat a variety of cancers and other conditions involving inflammation and thrombosis, or blood clotting.
Massey’s bone marrow transplant unit receives Beacon Award for Excellence
The inpatient bone marrow transplant (BMT) unit at VCU Massey Cancer Center is the first of its kind in the nation to earn the American Association of Critical-Care Nurses (AACN) Beacon Award for Excellence. A BMT is a procedure that replaces damaged or destroyed bone marrow with healthy bone marrow stem cells in the treatment of blood cancers like leukemia and lymphoma and other blood and immune disorders. The AACN Beacon Award for Excellence recognizes individual units that distinguish themselves by improving every facet of patient care.
Novel gene target shows promise for bladder cancer detection and treatment
Scientists from Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have provided evidence from preclinical experiments that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) could be used as a therapeutic target to kill bladder cancer cells, help prevent metastasis and even be used to non-invasively diagnose the disease and monitor its progression. The study, published in the journal Clinical Cancer Research, was a collaborative effort between Paul B. Fisher, M.Ph., Ph.D., who originally discovered the mda-9/syntenin gene, and Santanu Dasgupta, Ph.D., an expert in bladder cancer research.